OncoGenesis

Catherine Calarco is a proven CEO and growth executive with a successful track record in scaling companies, launching award-winning technologies, and driving revenue growth in the AI, MedTech, and women’s health sectors. With experience leading Thermo Fisher/Biolab, Automation Anywhere, and HeartMath. Catherine serves as a Board Director at Optomed Plc, a global leader in AI-powered vision screening. She has raised millions in capital, secured large strategic partnerships, including Kaiser, and driven product innovation in women’s health, with a focus on biofeedback, menopause, and diagnostics. Catherine has also advised companies like Nerbio and MIT startups, guiding them through market expansion and fundraising. Her expertise in AI, MedTech, and regulatory strategy drives impactful growth and acquisition. As a Lecturer and Graduate of MIT Sloan School of Management, Catherine advised CEOs on investment strategies and scaling profitable growth. A renowned speaker and thought leader, she hosts the ""Humanity Evolve"" radio show. A passionate advocate for women’s leadership, Catherine is an honored member of the Exceptional Women’s Alliance, Avante Capital WON and Astia.org. In addition to her work as CEO with OncoGenesis, Catherine also works approximately 25 hours a week working as CXO of Digital Health and as an Executive Consultant for Calarco Consulting.

Peter Gombrich is a serial entrepreneur who successfully founded three medical device companies. Under his leadership, he raised over $300 million and took several companies public. Peter founded OncoGenesis in 2008 and has been working in molecular diagnostics for women's health for more than ten years. Before founding OncoGenesis, he founded Diamics, a women's healthcare company focused on cervical cancer screening. From 1992 to 2006, Peter founded and led AccuMed/Molecular Diagnostics, a cytopathic laboratory products company, which he took public. From 1985 to 1992, he founded and was CEO of CliniCom, a bedside clinical information provider that McKesson acquired. Before CliniCom, Peter founded and was CEO and Chairman of Integrated Microcircuits, an outgrowth of St. Jude Medical. From 1976 to 1982, he co-founded St. Jude Medical, the world's largest heart valve company. Before St. Jude, he held various sales and marketing positions in several medical device companies, including Medtronic and Beckman Instruments. Peter has a BS degree in electrical engineering and an MBA from the University of Denver.

Adam Henry is currently the Senior Vice President of Corporate Development at point-of-care instrument manufacturer, Proof Diagnostics, bringing over 25 years of biotechnology industry experience to the company. Adam’s career functional responsibilities have ranged in scope from corporate strategy, business development (M&A) and marketing, specifically within the molecular diagnostics arena over the past 13 years, to product development, R&D and operations as a product design engineer earlier in his career at Invitrogen (now part of Thermo Fisher Scientific) and Dura Pharmaceuticals (acquired by Elan Pharmaceuticals). Prior to joining Proof Dx in May 2022, Adam served as Head of Strategy and Business Development at Roche-subsidiary GenMark Dx. Before that, he held senior management roles at Siemens Healthineers, Hologic and Gen-Probe (acquired by Hologic) in strategy, business development and upstream marketing. During his tenure, Gen-Probe launched several highly innovative products including the PANTHER® molecular diagnostic system and the APTIMA® HPV screening assay, and the company’s value doubled, creating nearly $2 billion in value for shareholders, culminating in a successful sale of the business to Hologic in 2012. In total, Adam has facilitated nearly $6 billion in molecular diagnostics transactions since 2009. Mr. Henry holds an MBA from the UCLA Anderson School of Management and a BS degree in Mechanical Engineering from the University of Nevada.

Scott brings more than 40 years of medical device and diagnostics industry experience to OncoGenesis. He has served in various senior management positions within OncoGenesis and is a member of the Board of Directors. Scott's in-depth knowledge includes positions at Johnson & Johnson, 3M Healthcare, and Medtronic. Scott served as CEO of Bentec Medical, leading to a successful exit to strategic buyers. Scott also served as CEO of start-up Dynatherm Medical bringing the Company from concept to market to successful acquisition by Care Fusion. As President of Oridion Medical, he built market presence and revenues, leading to a successful IPO in Europe. Scott holds a BS in Chemistry from the University of California - Davis and an MBA from the University of California - Irvine.

Tom Umbel has been the President and CEO of Seno Medical since January of 2016. Tom led the Business Development efforts at Hologic, the largest dedicated Women's Health company in the U.S. Tom's role in managing mergers and acquisitions helped grow Hologic from a small single-product company with $100 million in revenue to a large, diversified company with more than $2.5 billion during his 15 years. Among his Hologic accomplishments, he led the acquisition of Cytyc ($6.6 billion) and GenProbe. Prior to Hologic, Tom was President of Direct Radiography Corp. (DRC). He led the development and commercialization of the digital x-ray detector technology, which he ultimately sold to Hologic in 1999. This core market-leading digital mammography system is their engine to significant growth. Tom continues to serve on many medical device and diagnostic company boards. Tom holds a BS Science degree in chemical engineering from Grove City College.